EN | UA
EN | UA

Help Support

Back

CGRP-targeted therapies: A future scope of migraine and cluster headache treatment

CGRP-targeted therapies: A future scope of migraine and cluster headache treatment CGRP-targeted therapies: A future scope of migraine and cluster headache treatment
CGRP-targeted therapies: A future scope of migraine and cluster headache treatment CGRP-targeted therapies: A future scope of migraine and cluster headache treatment

What's new?

Published evidence on phase 2 or phase 3 clinical trials of CRRP-target therapies has shown promising results. Similar results in further studies can be expected.

Calcitonin gene-related peptide (CGRP) is a signaling neuropeptide released from activated trigeminal sensory afferents in a headache and facial pain disorders. There are a handful of CGRP-targeted treatments currently in phase III studies for an acute migraine treatment or prevention.

At present, there are four monoclonal antibodies [ALD403 (eptinezumab), AMG 334 (erenumab), LY2951742 (galcanezumab), and TEV-48125 (fremanezumab)] being studied for migraine prevention that target either the CGRP ligand or receptor.

In the meantime, one small-molecule CGRP receptor antagonist (ubrogepant, MK-1602) is currently in phase III studies for the treatment of migraine. Among these, two of the anti-CGRP monoclonal antibodies are also in clinical trials for cluster headache prevention. Many other small-molecular CGRP receptor antagonists are in earlier developmental stages for the treatment or prevention of an acute migraine. The current review emphasizes on the growing body of clinical trials studying CGRP-targeted therapies for migraine and cluster headaches.

Source:

Clin Neuropharmacol. 2017 Jun 21.

Article:

Calcitonin Gene-Related Peptide-Targeted Therapies for Migraine and Cluster Headache: A Review.

Authors:

Schuster NM et al.

Comments (0)

You want to delete this comment? Please mention comment Invalid Text Content Text Content cannot me more than 1000 Something Went Wrong Cancel Confirm Confirm Delete Hide Replies View Replies View Replies en
Try: